Effects of omalizumab therapy on peripheral nerve functions: short observational study.
Postepy Dermatol Alergol
; 36(2): 211-216, 2019 Apr.
Article
in En
| MEDLINE
| ID: mdl-31320856
ABSTRACT
INTRODUCTION:
Peripheral neuropathy (PN) is a common neurological condition causing symmetrical and diffuse damage in nerves. The etiology of PN includes systemic diseases, toxic exposure, medications, infections, and hereditary diseases. Omalizumab is a humanized monoclonal anti-IgE antibody that exerts its activity by binding to free IgE in circulation.AIM:
To investigate the relationship between omalizumab and peripheral neuropathy. MATERIAL ANDMETHODS:
The study included 30 patients who underwent omalizumab therapy (Xolair) due to the diagnosis of chronic urticaria. A detailed neurological and physical examination was performed in each patient both before and 3 months after the therapy. Electrophysiological examination was also performed using a Medelec Synergy instrument.RESULTS:
The 30 patients included 8 (26.7%) men and 22 (73.3%) women with a mean age of 37.5 ±14.14 years. No serious side effect of the medication was detected in any patient although local wound irritation occurred in 3 (10%) patients. Moreover, no change occurred in the pre-treatment Neuropathy Symptom Score (NSS) or Neurological Disability Score (NDS) of the patients and no pathological values that could result in neuropathy were observed during motor/sensory nerve conduction. However, significant changes were detected in the sensory and motor components of the nerves with regards to pre- and post-treatment values.CONCLUSIONS:
Omalizumab therapy caused no peripheral neuropathy in any of our patients but altered the latency, amplitude, and velocity values of the peripheral nerves.
Full text:
1
Database:
MEDLINE
Type of study:
Observational_studies
Language:
En
Year:
2019
Type:
Article